Text Only Page



$2M Grant to Support Trent-Based International Consortium on Anti-Virals
March 3, 2007

Peterborough MP Dean Del Mastro announced today that the federal government will provide $2 million to support the next development phase of the International Consortium on Anti-Virals (ICAV), headquartered at Trent University.

ICAV is a non-profit Canadian consortium established to discover and develop new therapeutic interventions for viral infections. Comprising more than 200 scientists from 18 countries, ICAV links their research with private sector partners to facilitate knowledge transfer and effective use of limited resources to accelerate the development and delivery of drugs that target viral diseases worldwide.

The March 23 ICAV AnnouncementThe funding announced today will aid in the establishment of the international headquarters for ICAV in Peterborough at Trent University.

“ICAV is an extraordinary example of international collaboration that brings together some of the best minds, expertise and social commitment possible to work toward solutions needed world wide,” said President Bonnie Patterson of Trent University. “We are very excited that Trent is the home administrative base to ICAV and that a number of our faculty will have a role to play in this significant international team of talented people.” President Patterson noted that Trent faculty and students, who add so much to Trent’s reputation for research excellence, will be introduced to acclaimed scientists who are developing the anti-virals required to respond to the threat of an international pandemic.

“This funding significantly enhances our efforts to get the discoveries out of the universities and into the marketplace,” explained Dr. Jeremy Carver, chief executive and chief science officer of ICAV. “ICAV operates using a unique model designed to generate revenues through pharmaceutical royalties in order to deliver anti-viral therapeutic interventions and expertise to combat global diseases such as HIV/AIDS, hepatitis B and C, dengue fever, West Nile virus and rotavirus infection in children and many others.”

Effective and readily available anti-viral therapies are an essential element of pandemic preparedness plans and global health in general. A first-line of defence against emerging pandemics, anti-virals provide protection while a vaccine is developed. Anti-viral drugs can also provide effective treatment for diseases where a vaccine has yet to be identified. Traditional, commercial approaches to drug-development, however, have failed to yield a viable pipeline of anti-viral drugs, particularly for emerging viral diseases and viruses of the developing world.

For further information about ICAV, please visit www.icav-citav.com .